Aptose Biosciences Inc. (TSE:APS – Get Free Report) (NASDAQ:APTO)’s share price reached a new 52-week low during mid-day trading on Tuesday . The company traded as low as C$0.16 and last traded at C$0.17, with a volume of 199872 shares trading hands. The stock had previously closed at C$0.21.
Aptose Biosciences Stock Performance
The company has a current ratio of 1.05, a quick ratio of 5.41 and a debt-to-equity ratio of -117.37. The firm’s fifty day moving average is C$0.30 and its 200 day moving average is C$0.42. The company has a market cap of C$7.10 million, a PE ratio of -0.03 and a beta of 1.36.
Aptose Biosciences Company Profile
Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.
Featured Articles
- Five stocks we like better than Aptose Biosciences
- NYSE Stocks Give Investors a Variety of Quality Options
- NVIDIA Stock: A Market Barometer in Tech’s Turbulent Times
- How to Short Nasdaq: An Easy-to-Follow Guide
- Palantir Stock Nears Bear Market Territory – Why and What’s Next?
- Where Do I Find 52-Week Highs and Lows?
- Home Depot Turns a Corner: New Highs Likely This Year
Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
